- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04582344
Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)
August 3, 2022 updated by: Health Institutes of Turkey
Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
This study is a randomized, double-blinded, and placebo controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd.
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental vaccine in healthy adults aged 18~59 Years.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized, double-blinded, multi-center, placebo-controlled phase III clinical trial in adults aged 18~59 years.
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental SARS-CoV-2 inactivated vaccine.
The experimental vaccine and placebo were both manufactured by Sinovac Research & Development Co., Ltd.
A total of 13.000 subjects will be enrolled.
Participant will be assigned to receive two doses of experimental vaccine or placebo on the schedule of day 0,14.
It is planned that the study will be conducted with two separate cohorts.
The first cohort will be healthcare workers in the high risk group (K-1) and the second cohort will be people at normal risk (K-2).
After 2 doses of vaccination of 1300 volunteers are completed, safety data will be evaluated by the data safety monitoring board without breaking the blinding, and if there is no safety issue, the K2 cohort will continue to be vaccinated.1.300
volunteers, including 650 volunteers SARS-CoV-2 vaccine and placebo arms, will be included in the K-1 cohort.
In the K-2 cohort (normal risk group for COVID-19), 7.650 volunteers were planned to be included in the SARS-CoV-2 vaccine group, and 3.500 volunteers in the placebo group.
Study Type
Interventional
Enrollment (Actual)
10214
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Adana, Turkey
- Çukurova University Faculty of Medicine, Department of Infectious Diseases
-
Ankara, Turkey
- Hacettepe University Faculty of Medicine Department of Infections Diseases and Clinical Microbiology
-
Ankara, Turkey
- T.C Ministry of Health Ankara Provincial Health Directorate Health Sciences University Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital
-
Antalya, Turkey
- Akdeniz University Faculty of Medicine, Department of Infectious Diseases
-
Bursa, Turkey
- Bursa Uludağ University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
-
Diyarbakır, Turkey
- Dicle University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
-
Gaziantep, Turkey
- Gaziantep University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
-
Istanbul, Turkey
- Acıbadem Atakent Hospital, Infectious Diseases and Clinical Microbiology
-
Istanbul, Turkey
- Cerrahpaşa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology
-
Istanbul, Turkey
- Istanbul University Istanbul Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
-
Istanbul, Turkey
- T.R. Ministry of Health Istanbul Provincial Health Directorate Prof. Dr. Cemil Taşçıoğlu City Hospital, Infectious Diseases Clinic
-
Istanbul, Turkey
- University of Health Sciences İstanbul Ümraniye Training and Research Hospital
-
Istanbul, Turkey
- Istanbul Medipol University Faculty of Medicine, Department of Internal Medicine
-
Istanbul, Turkey
- T.R. Ministry of Health Istanbul Provincial Health Directorate Marmara Univesity Istanbul Pendik Education and Research Hospital
-
Istanbul, Turkey
- T.R. Ministry of Health Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital
-
Kayseri, Turkey
- T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department
-
Kocaeli, Turkey
- Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
-
Malatya, Turkey
- Malatya İnönü University Faculty of Medicine, Department of Infectious Diseases
-
Trabzon, Turkey
- Karadeniz Technical University Medical Faculty Hospital, Department of Infectious Diseases and Clinical Microbiology
-
İzmir, Turkey
- Ege University Faculty of Medicine Hospital, Department of Infectious Diseasesaculty of Medicine Hospital, Department of Infectious Diseases
-
İzmir, Turkey
- T.R. Ministry of Health İzmir Provincial Health Directorate İzmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases
-
İzmir, Turkey
- Republic Of Turkey Ministry Of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital
-
-
Turkey Region
-
Ankara, Turkey Region, Turkey, 06800
- T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic
-
Ankara, Turkey Region, Turkey, 06800
- T.R. Ministry of Health Ankara Provincial Health Directorate Ankara Training and Research Hospital, Infectious Diseases
-
Ankara, Turkey Region, Turkey
- Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 59 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-59 years of age (including 18 and 59 years of ages),
- For only K1 cohort, health care workers such as medical doctor, nurse, ward boy, cleaner, hospital technician, administrative personnel who work in any department of a hospital.
- Signed informed consent
Exclusion Criteria:
- Previously PCR positive for COVID-19
- IgG or IgM is positive
- For females: Pregnancy (confirmed by positive beta-hCG test), breastfeeding or intent to engage in sexual relations with reproductive intent without use of birth control methods in the three months following vaccination
- Known allergy to components of the study vaccine or control
- Use of immunosuppressant therapy regimens within the six months prior to enrollment in the study or planned use within the two years following enrollment. Immunosuppressant therapy regimens include: antineoplastic chemotherapy, radiation therapy and immunosuppressants to induce transplant tolerance, among others
- Use of immunosuppressive doses of corticosteroids within the three months prior to the enrollment in the study and planned use of immunosuppressive doses of corticoids within the three months following enrollment in the study. Immunosuppressive doses of corticosteroids will be considered the equivalent prednisone 20 mg/day for adults, for longer than one week. Continued use of topical or nasal corticosteroids is not considered an immunosuppressant
- History of asplenia
- History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture
- Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has caused medical, professional or family problems, indicated by clinical history
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- Participation in another clinical trial with an investigational product in the six months prior to enrollment in the study or planned participation in another clinical trial within the two years following enrollment
- Received live attenuated virus vaccine 14 days prior to enrollment in the study
- Inactivated vaccine or sub unit vaccine 7 days prior to enrollment in the study
- Fever (oral temperature >37.2℃, axillary temperature will not be accepted) within the past 24 hours
- Any other condition that, in the opinion of the principal investigator or his/her representative physician, could put the safety/rights of potential participants at risk or prevent them from complying with this protocol.
- Any confirmed or suspected autoimmune disease or immunodeficiency disease, including human immunodeficiency virus (HIV) infection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SARS-COV-2 Vaccine
600 SU of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 14 days apart.
|
Two doses at 14-day interval, each inoculation dose is 0.5 mL.
Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
|
Placebo Comparator: Placebo
Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, intramuscular injection, two doses given 14 days apart.
|
Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19
Time Frame: 2 weeks after the second dose of vaccination
|
The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19
|
2 weeks after the second dose of vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Protection Indexes of One Vaccine Dose For Symptomatic COVID-19
Time Frame: 2 weeks after the second dose of vaccination
|
The protection rate of, at least, one dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19 Two weeks after the last dose vaccination.
|
2 weeks after the second dose of vaccination
|
Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity/and Death
Time Frame: 2 weeks after the second dose of vaccination
|
The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against rates of hospitalization, disease severity/and death two weeks after the second dose of vaccination
|
2 weeks after the second dose of vaccination
|
Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection
Time Frame: 2 weeks after the second dose of vaccination
|
The protection rate of a two dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed SARS-CoV-2 infection two weeks after the second dose of vaccination
|
2 weeks after the second dose of vaccination
|
Safety indexes of adverse reactions in 28 days
Time Frame: 28 days after the second dose of vaccination
|
The incidence of adverse reactions from the day of first vaccination to 28 days after the second dose of vaccination.
|
28 days after the second dose of vaccination
|
Safety indexes of adverse reactions in 7 days
Time Frame: 7 days after each dose of vaccination
|
The incidence of adverse reactions within 7 days after each dose of vaccination
|
7 days after each dose of vaccination
|
Safety indexes of serious adverse events in 1 year
Time Frame: 1 year after second dose of vaccination
|
The incidence of SAEs from the first vaccination to one year after the second dose vaccination
|
1 year after second dose of vaccination
|
Immunogenicity parameters (seroconversion rate, seropositivity rate) in 14 days
Time Frame: 14 days after each dose vaccination
|
The seroconversion rate, seropositivity rate 14 days after each dose vaccination
|
14 days after each dose vaccination
|
Immunogenicity parameters (seroconversion rate, seropositivity rate) in 28 days
Time Frame: 28 days after the second dose vaccination
|
The seroconversion rate, seropositive rate 28 days after the second dose vaccination
|
28 days after the second dose vaccination
|
Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 14 days
Time Frame: 14 days after each dose vaccination
|
GMT and GMI of neutralizing antibody and IgG 14 days after each dose vaccination
|
14 days after each dose vaccination
|
Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 28 days
Time Frame: 28 days after the second dose vaccination
|
GMT and GMI of neutralizing antibody and IgG 28 days after the second dose vaccination
|
28 days after the second dose vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Murat Akova, Prof., Faculty Member
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.
- Luan N, Li T, Wang Y, Cao H, Yin X, Lin K, Liu C. Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. Front Immunol. 2022 Apr 8;13:882856. doi: 10.3389/fimmu.2022.882856. eCollection 2022.
- Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, Kose S, Erdinc FS, Akalin EH, Tabak OF, Pullukcu H, Batum O, Simsek Yavuz S, Turhan O, Yildirmak MT, Koksal I, Tasova Y, Korten V, Yilmaz G, Celen MK, Altin S, Celik I, Bayindir Y, Karaoglan I, Yilmaz A, Ozkul A, Gur H, Unal S; CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. Erratum In: Lancet. 2022 Jan 29;399(10323):436.
- Akova M, Unal S. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2020
Primary Completion (Actual)
June 30, 2022
Study Completion (Anticipated)
August 31, 2022
Study Registration Dates
First Submitted
October 1, 2020
First Submitted That Met QC Criteria
October 8, 2020
First Posted (Actual)
October 9, 2020
Study Record Updates
Last Update Posted (Actual)
August 4, 2022
Last Update Submitted That Met QC Criteria
August 3, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9026-ASI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on CoronaVac
-
Institut Pasteur de TunisCompleted
-
The University of Hong KongActive, not recruiting
-
University of Sao Paulo General HospitalCompletedHIV Infections | COVID-19 | Safety Issues | AIDS | Rheumatic Disease | ImmunogenicityBrazil
-
Sinocelltech Ltd.Not yet recruitingCOVID-19 SARS-CoV-2 Infection
-
Hospital do Rim e HipertensãoActive, not recruitingCoronavirus Infection | Vaccine Adverse Reaction | SARS-CoV InfectionBrazil
-
AIM Vaccine Co., Ltd.Not yet recruiting
-
Health Institutes of TurkeyCompleted
-
Health Institutes of TurkeyCompleted
-
Health Institutes of TurkeyCompleted
-
Health Institutes of TurkeyActive, not recruitingCOVID-19 | Sars-CoV-2 InfectionTurkey